Brief: Biomarin Presents New Data On The Effect Of Long-Term Treatment With Voxzogo® (Vosoritide) On Arm Span, Bone Health And Growth In Children With Achondroplasia
02/05/2026 20:38
May 2 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O: BIOMARIN PRESENTS NEW DATA ON THE EFFECT OF LONG-TERM TREATMENT WITH VOXZOGO® (VOSORITIDE) ON ARM SPAN, BONE HEALTH AND GROWTH IN CHILDREN WITH ACHONDROPLASIA AT THE PEDIATRIC ENDOCRINE SOCIETY'S 2026 ANNUAL MEETING Source text: ID:nPn9Dts18a Further company coverage: BMRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife